IRVINGTON, N.Y.--(BUSINESS WIRE)--MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the closing of its previously announced $12.45 million private placement of convertible preferred stock, common stock warrants and common stock. Net proceeds to the Company from this offering are approximately $11.5 million.
Help employers find you! Check out all the jobs and post your resume.
